HealthDay News — New guidelines have been presented for the use of systemic and topical fluoroquinolones in children in a clinical report recently published in Pediatrics.

Mary Anne Jackson, MD, and colleagues from the American Academy of Pediatrics Committee on Infectious Diseases discuss the use of systemic and topical fluoroquinolones in children.

The researchers note that fluoroquinolones are broad-spectrum agents which should be considered for use in specific situations. 

These include infection caused by a multi-drug-resistant pathogens for which there is no alternative that is safe and effective and for situations in which oral fluoroquinolone therapy is an acceptable alternative to parenteral non-fluoroquinolone therapy. 

Fluoroquinolones may also represent a preferred option or an acceptable alternative to standard therapy due to concerns of antimicrobial resistance, toxicity or tissue penetration characteristics.

“In the case of fluoroquinolones, as is appropriate with all antimicrobial agents, prescribing clinicians should verbally review common, anticipated and potential adverse events, such as rash, diarrhea and potential musculoskeletal or neurologic events and indicate why a fluoroquinolone is the most appropriate antibiotic agent for a child’s infection,” the authors write.

Reference

Jackson MA and Schutze GE. “The Use Of Systemic And Topical Fluoroquinolones”. Pediatrics. 2016. 138(5): e20162706-e20162706. doi: 10.1542/peds.2016-2706. [Epub ahead of print]

Related Articles